CAR mediated Pharmacodynamics (PD) & Immune Phenotypical Biomarker Analysis Services

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Despite remarkable clinical responses, CAR-T therapy faces persistent challenges including unpredictable in vivo expansion, heterogeneous differentiation fates, and a lack of reliable surrogate biomarkers that link early cellular kinetics to durable remission or toxicity. Our CAR-Mediated Pharmacodynamics (PD) & Immune Phenotypical Biomarker Analysis platform offers an integrated, multi-dimensional assessment of CAR^-T cell behavior and host immune remodeling across the entire therapeutic timeline. Our service combines high-parameter flow cytometric phenotyping, absolute lymphocyte subset quantitation, and high-resolution immune repertoire sequencing to deliver a cohesive view of both CAR-specific and global immune dynamics. By bridging cellular pharmacodynamics with systems-level immune architecture, we empower you to deconvolve response heterogeneity, rationalize combination regimens, and identify early predictive biomarkers that guide clinical decision-making and accelerate candidate advancement.

Introduction

CAR therapy represents a paradigm-shifting immunotherapeutic modality that redirects polyclonal T cell cytotoxicity against tumor-associated antigens through engineered receptor signaling domains, yet its clinical efficacy remains inherently heterogeneous across patients and cancer types. Biomarkers, ranging from baseline tumor microenvironmental features and systemic inflammatory indices to post-infusion soluble factors and surface protein dynamics, have emerged as critical correlates of response and resistance, offering both prognostic stratification and mechanistic insight into therapy outcome. Complementing these static or dynamic readouts, pharmacokinetic (PK) profiling of CAR‑T cells, encompassing expansion, persistence, and trafficking kinetics, provides an indispensable quantitative framework that bridges cellular behavior with exposure‑response relationships.

Fig.1 The role of biomarkers is central to predicting CAR T therapy outcomes. (OA Literature) Fig.1 Biomarkers are key factors in predicting CAR T therapy outcomes.¹

Our Service

Our platform integrates CAR-T functional kinetic profiling with exhaustion-state mapping and high-dimensional immunophenotyping to yield quantitative PD readouts. By converting dynamic cellular behaviors into clinically interpretable biomarkers, we enable refined patient stratification, early response forecasting, and biology-informed trial design, all delivered with validated, submission-ready analytical standards to expedite your immuno-oncology development.

Service Packages

Lymphocyte Subset Profile & Absolute Cell Count Analysis (TBNK FACS)

Our service provides a foundational immunophenotypic baseline and longitudinal tracking of major lymphocyte compartments through multiparameter flow cytometry with absolute quantitation. It enables precise monitoring of immune reconstitution, lymphodepletion efficiency, and homeostatic shifts post-CAR infusion, while also serving as a critical quality-control anchor for interpreting downstream functional and phenotypic readouts.

Learn More →

In vivo Transduced CAR⁺ T-Cell Phenotypic & Differentiation Analysis

Our service focuses on the dynamic characterization of engrafted CAR⁺ T cells directly ex vivo, profiling their surface marker signatures, exhaustion status, activation states, and memory/differentiation hierarchies without in vitro manipulation. By capturing the actual differentiation trajectory and functional fitness of CAR⁺ cells in the host microenvironment, this analysis reveals critical determinants of persistence, proliferative capacity, and cytotoxic potential.

Learn More →

Post-CAR Therapy BCR/TCR Immune Repertoire Clonality & Diversity Analysis (BCR/TCR-Seq)

Our service leverages high-throughput sequencing of rearranged immunoglobulin and T cell receptor loci to decode the global architecture of adaptive immune diversity following CAR therapy, with particular emphasis on clonal expansion dynamics, repertoire evenness, and shared public clones. It enables tracking of CAR-induced T cell clonal dominance, emergence of tumor-reactive bystander clones, and potential B cell aplasia-associated repertoire contraction, while also uncovering oligoclonal patterns that may correlate with cytokine release syndrome or neurotoxicity.

Learn More →

Our Service Process

Required Starting Materials:

CAR-T cell product.
Patient peripheral blood samples.

Key Steps:

Workflow of CAR-mediated pharmacodynamics (PD) & immune phenotypical biomarker analysis at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Predictive biomarkers.
Mechanistic PK-PD relationships.

Key Advantages

Dynamic Prediction of Individualized Therapeutic Response: This approach surpasses static measurements by integrating time-dependent immune parameters, thereby enabling early and precise prediction of clinical outcomes such as complete remission.
Early Warning of Relapse Risk: It identifies key surrogate markers, including premature B-cell recovery and endogenous CD8⁺ T-cell exhaustion signatures, that serve as robust indicators of impending treatment failure.
Functional Characterization of the CAR-T Cell Product: Immunophenotyping provides a detailed assessment of the cellular composition of the CAR-T product, directly establishing a correlation between the proportion of specific memory T cell subsets and superior in vivo expansion capacity as well as sustained therapeutic durability.

FAQ

Q1: Which biomarkers predict severe CRS and ICANS?

A1: Baseline systemic inflammation markers predict both poor efficacy and severe CRS. Notably, a higher proportion of naïve/stem-cell memory T cells in the product correlates with enhanced efficacy yet a reduced risk of severe CRS and ICANS.

Q2: What baseline biomarkers predict CAR-T efficacy?

A2: Efficacy prediction hinges on three factors: (1) a higher frequency of early-memory T cells (Tcm/Tscm) in the product, with non-exhausted effector-memory-like cells driving low-dose efficacy; (2) elevated baseline IL-6, CRP, and ferritin signaling inferior survival; and (3) CAR-structure specificity—predictive T cell signatures differ between CD28- and 4-1BB-costimulated products, necessitating stratified modeling.

Why Choose Us?

Our platform integrates real-time CAR-T pharmacodynamic profiling with high-dimensional immune phenotyping, linking effector kinetics to biomarker-driven responses. We deliver actionable insights through validated assays, precise data normalization, and translational analytics, accelerating your candidate selection, dosing strategies, and patient stratification with reproducibility and regulatory-grade rigor.

How to contact us?

Interested in advancing your CAR-T candidate? Our scientific liaisons are available for private, project-focused discussions. Expect tailored assay blueprints, prompt budgetary estimates, and informed strategic input—all aligned with your development milestones. Reach us via email to arrange an initial technical briefing.

Reference

Levstek, Lucija et al. "Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives." Frontiers in immunology vol. 15 1378944. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2024.1378944.